To read the full article sign up for free or sign in.

Astellas in-licenses 4DMT’s gene therapy vector for rare ophthalmic targets in $942M deal

July 11, 2023

Astellas Pharma Inc. and 4D Molecular Therapeutics Inc. (4DMT) inked a deal worth up to $942 million under which Astellas will license 4DMT's intravitreal R100 gene therapy vector for rare ophthalmic targets.

BioWorld BioWorld Asia Deals and M&A Ocular Japan

Today's news in brief

BioWorld

BioWorld briefs for Sept. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 19, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...

The domino effect of cutting mRNA vaccine research

BioWorld

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing...